Gedatolisib
Drug Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Gedatolisib |
| Trade Name | Revtorpyk |
| Synonyms | PKI-587|PF-05212384|PF 05212384 |
| Drug Descriptions |
Revtorpyk (gedatolisib) is an ATP-competitive inhibitor that targets phosphatidylinositol 3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in the PI3K/mTOR signaling pathway, and may result in antitumor activity, including inhibition of tumor growth and tumor regression (PMID: 21325073, PMID: 31822716). Revtorpyk (gedatolisib) is FDA-approved for use in combination with Faslodex (fulvestrant), with or without Ibrance (palbociclib) in patients with hormone receptor-positive, ERBB2 (HER2)-negative locally advanced or metastatic breast cancer without a PIK3CA mutation (FDA.gov). |
| DrugClasses | mTOR Inhibitor 51 PI3K Inhibitor (Pan) 43 |
| CAS Registry Number | 1197160-78-3 |
| NCIT ID | C91732 |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
CKB BOOST